Q2-FY25 · Neeraj Kanwar
My mantra has been profitable growth. And therefore, we are only looking at premiumization of our PCR tires and not going down on pricing.
Apollo Tyres · tone and specificity signals across the available quarters.
Language signals
My mantra has been profitable growth. And therefore, we are only looking at premiumization of our PCR tires and not going down on pricing.
We are doing more analysis to see what has gone wrong and where other expenses have gone up. So, there is a direct focus on all of this.
The under-recovery from last year is about 6-odd percent.
Profitable growth continues to be our mantra, and we will continue to keep our focus on profitability, free cash flows, and on return ratios.
We will not go the pricing route, and that's been a consistent strategy. It will be a mix of brand, product, and expansion of the distribution channels.
At the end of the day, the tire is a performance product. It is not a showpiece to be displayed somewhere.
We are trying to vacate the 12-inch, 13-inch market, especially with the OEMs, and then going upsizing of 14, 15, 16, 17, which is where more profitability is concerned.
The priority to profitability margins will continue to be there. And yes, a couple of our peers have definitely done better than us.
Currently, given the market situation, etc., and the overall scenario, absolute near-term, no price increase is planned.
We closed Q3 with consolidated top-line growth of nearly 12% and an EBITDA margin of 15.3%.
Our current capacity utilization level in India is in the high 80s, and given our growth expectations for the near future, we would start hitting capacity limitations soon.
We would probably need to take a mid-single-digit kind of price increase every year.
We have already announced price increases of 6%-8% for this current quarter. More price increases would further be needed.
The closure of the Enschede plant production remains on track. A non-cash write-off of EUR 43 million has been taken on the fixed assets this quarter.
Our net debt to EBITDA ratio has significantly improved from 3.2x multiple to 0.4x in 2026 March, providing us with ample financial strength to navigate future uncertainties with confidence.